Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

• Obesity
• Hepatic Insufficiency

• Drug: CP-945,598
  
  Administration of CP-945,598 in subjects with mild hepatic function
• Drug: CP-945,598
  
  Administration of CP-945,598 in subjects with moderate hepatic function
• Drug: CP-945,598
  
  Administration of CP-945,598 in subjects with normal hepatic function

• Experimental: Mild hepatic function
  
  Intervention: Drug: CP-945,598
• Experimental: Moderate hepatic function
  
  Intervention: Drug: CP-945,598
• Experimental: Normal hepatic function
  
  Intervention: Drug: CP-945,598

Inclusion Criteria:

• Healthy:Matched for age (± 5 years), weight (± 10 kg), and gender (±2 subjects per gender)
• Subjects with hepatic disease: 1. mild impairment (child-pugh score 5-6), moderate (child-pugh score 7-9). 2. stable hepatic disease: no changes in the last 30 days. 3. stable dose of medication and/or treatment.

Exclusion Criteria:

• All subjects: Non-prescribed use of drugs of abuse/recreational drugs; recent treatment with experimental drugs or herbal experiments; ECG and blood pressure falling outside of protocol-specified limits; history of regular tobacco use exceeding protocol-specified limits
• Normal subjects: medically important health conditions; recent use of prescription or non-prescription medications; history of regular alcohol use exceeding protocol-specified limits
• Subjects with hepatic disease: child-puge score greater than 9; hepatic carcinoma and hepatorenal syndrome;Undergone porta-caval shunt surgery; History of GI hemorrhage due to esophageal varices or peptic ulcers less than 1 month prior to study entry; significant hepatic encephalopathy; severe ascites and/or pleural effusion; Positive blood alcohol test/alcohol breathalyzer at screening or on Day 0.